Post Marketing Surveillance on Propranolol and Atenolol Tablets Manufactured in Iran Title: PMS of propranolol and atenolol tablets
Iranian Journal of Pharmaceutical Sciences,
Vol. 6 No. 2 (2010),
1 April 2010
,
Page 83-90
https://doi.org/10.22037/ijps.v6.41254
Abstract
Propranolol, a prototypical b-adrenergic receptor antagonist and atenolol, a cardio-selective b-antagonist are widely used in therapeutic regimens for treatment of hypertensive patients. In Iran, several pharmaceutical manufacturers formulate these two b-blockers. As the formulation of a dosage form is essential for the patient's safety and drug efficacy, in this study we aimed to evaluate the quality of
the tablets which are formulated by the above manufacturers. Atenolol (100 mg) tablet manufactured by APOTEX in Canada also was evaluated. The commercially available preparations of the following dosage forms were studied: propranolol (10 mg, 40 mg) manufactured by TOLID DARU and ROSE DARU (a, b, c, d), atenolol (50 mg) manufactured by DARUPAKHSH (e), atenolol (100 mg) manufactured by DARUPAKHSH, TOLID DARU, SOBHAN, LORESTAN and APOTEX (f, g, h,i, j). The quality and safety of the dosage forms of these drugs were evaluated by PMS studies. For this purpose, the weight variation, hardness, thickness, content assay, content uniformity, disintegration time and dissolution rate of the dosage forms were compared to British Pharmacopeia (BP) and United States Pharmacopeia (USP) standards. The results verify that all dosage forms show evidence of the USP and BP quality assessment.
- Propranolol
- Atenolol
- PMS
- Tablet
How to Cite
References
[2] Fontanarosa PB; Rennie D, DeAngelis CD. Post marketing surveillance- lack of vigilance, lack of trust. JAMA 2004; 292: 2647-50.
[3] Fell PJ, Watson NP, O'Donnell HF. Post marketing drug surveillance: another string to the bow. Eur J Clin Pharmacol 1978; 13: 315-6.
[4] Gibbons GH. Post marketing surveillance of prescription drugs. U.S. government printing office, Washington D.C., 1982.
[5] Fernandes C, Junqueira RG, Campos LMM, Pianetti GA. Dissolution test for lamivudine tablets: optimization and statistical analysis. J Pharm Biomed Anal 2006; 42: 601-6.
[6] Chrustalev OA, Moshejko ME, Gerasimov VG, Galimskaja LJ, Rjabichin EA, Patrunova OS, Konopljanik NV. Talinolol in Patients with stable angina pectoris and concomitant hypertension. J Clin Basic Cardiol 2000; 3:129-32.
[7] British Pharmacopoeia, London. The Stationary Office, 1999.
[8] United States Pharmacopea, 23, Rockville, 1995.
[9] Lackman L, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy, third ed., Philadelphia, 1986.
[10] Siddiqui A, Nazzal S. Measurement of surface color as an expedient QC method for the detection of deviations in tablet hardness. Internat J Pharma 2007; 341: 173-80.
[11] Cora´ LA, Fonseca PR, Ame´rico MF, Oliveira RB, Baffa O, Miranda JRM. Influence of compression forces on tablets disintegration by AC biosusceptometry. Eur J Pharma Biopharm 2008; 69: 372-9.
[12] Banakar UV. Pharmaceutical dissolution testing, Marcel Dekker, New York. 1991.
[13] Late SG, Yu YY, Banga AK. Effects of disintegration-promoting agent, lubricants and moisture treatment on optimized fast disintegrating tablets. Internat J Pharm 2009; 365: 4-11.
- Abstract Viewed: 262 times
- IJPS_Volume 6_Issue 2_Pages 83-90 Downloaded: 173 times